"Immunotherapy" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Manipulation of the host's immune system in treatment of disease. It includes both active and passive immunization as well as immunosuppressive therapy to prevent graft rejection.
| Descriptor ID |
D007167
|
| MeSH Number(s) |
E02.095.465.425
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Immunotherapy".
Below are MeSH descriptors whose meaning is more specific than "Immunotherapy".
This graph shows the total number of publications written about "Immunotherapy" by people in this website by year, and whether "Immunotherapy" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 0 | 1 |
| 1998 | 0 | 2 | 2 |
| 1999 | 2 | 1 | 3 |
| 2000 | 1 | 3 | 4 |
| 2001 | 2 | 5 | 7 |
| 2002 | 3 | 3 | 6 |
| 2003 | 3 | 4 | 7 |
| 2004 | 5 | 7 | 12 |
| 2005 | 3 | 3 | 6 |
| 2006 | 5 | 2 | 7 |
| 2007 | 4 | 1 | 5 |
| 2008 | 7 | 5 | 12 |
| 2009 | 4 | 2 | 6 |
| 2010 | 7 | 5 | 12 |
| 2011 | 5 | 5 | 10 |
| 2012 | 8 | 7 | 15 |
| 2013 | 8 | 10 | 18 |
| 2014 | 9 | 10 | 19 |
| 2015 | 9 | 18 | 27 |
| 2016 | 20 | 2 | 22 |
| 2017 | 21 | 6 | 27 |
| 2018 | 32 | 16 | 48 |
| 2019 | 31 | 18 | 49 |
| 2020 | 21 | 27 | 48 |
| 2021 | 20 | 22 | 42 |
| 2022 | 4 | 29 | 33 |
| 2023 | 4 | 34 | 38 |
| 2024 | 23 | 27 | 50 |
| 2025 | 18 | 7 | 25 |
| 2026 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Immunotherapy" by people in Profiles.
-
Peripheral blood transcriptional profiling predicts tumor subtype and neoadjuvant chemoimmunotherapy outcomes in human breast cancer. Sci Transl Med. 2026 Apr 22; 18(846):eaec2358.
-
Triple negative breast cancer: what clinical progress have we seen in the last 5?years? Expert Opin Investig Drugs. 2026 Mar; 35(3):223-238.
-
Neoadjuvant vs perioperative chemo-immunotherapy according to pathological response in resectable non-small cell lung cancer: a reconstructed individual patient data meta-analysis. J Natl Cancer Inst. 2025 Nov 01; 117(11):2388-2393.
-
Clinical strategies for lung cancer management: Recommendations from the Bridging the Gaps Lung Cancer Consensus Conference 2024. Cancer. 2025 Sep 01; 131(17):e70060.
-
Progressive Immunotherapy-Related Mucocutaneous Eruption: A Mimicker of SJS-TEN. Am J Dermatopathol. 2025 Oct 01; 47(10):750-753.
-
Real-world effectiveness and safety of first-line chemoimmunotherapy combinations in metastatic non-small cell lung cancer with programmed death ligand-1?
-
Facts and Hopes in Radioimmunotherapy of Oligometastatic Disease. Clin Cancer Res. 2025 Jul 01; 31(13):2556-2564.
-
Immune Composition and Immunotherapy Outcomes of Mesothelioma With BAP1, CDKN2A, MTAP, and NF2 Alterations. J Thorac Oncol. 2025 Nov; 20(11):1615-1625.
-
Immune Subtyping Identifies Patients With Hormone Receptor-Positive Early-Stage Breast Cancer Who Respond to Neoadjuvant Immunotherapy (IO): Results From Five IO Arms of the I-SPY2 Trial. JCO Precis Oncol. 2025 Jun; 9:e2400776.
-
Potentiating cancer immunotherapies with modular albumin-hitchhiking nanobody-STING agonist conjugates. Nat Biomed Eng. 2025 Oct; 9(10):1719-1739.
People
People who have written about this concept.
Explore
_
Similar Concepts
Similar concepts derived from published works.
_
Top Journals
Top journals in which articles about this concept have been published.